<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: Behind The Curtain: That Secret Vytorin Panel</title>
	<atom:link href="http://www.pharmalot.com/2008/01/behind-the-curtain-that-secret-vytorin-panel/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2008/01/behind-the-curtain-that-secret-vytorin-panel/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 22:27:30 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: BPW</title>
		<link>http://www.pharmalot.com/2008/01/behind-the-curtain-that-secret-vytorin-panel/#comment-91925</link>
		<dc:creator>BPW</dc:creator>
		<pubDate>Fri, 11 Jan 2008 20:49:25 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2008/01/behind-the-curtain-that-secret-vytorin-panel/#comment-91925</guid>
		<description>Independent is all relative.  While they were independent of the ENHANCE study, they were all paid consultants for MSP.

I simply have a very tough time believing that Dave Orloff would have anything to do with recommending that MSP change the primary endpoint.  He used to head up the Metabolic/Endocrine division of the FDA and knows what regulatory agencies expect.  he also knows what is appropriate scientific conduct and what is not.</description>
		<content:encoded><![CDATA[<p>Independent is all relative.  While they were independent of the ENHANCE study, they were all paid consultants for MSP.</p>
<p>I simply have a very tough time believing that Dave Orloff would have anything to do with recommending that MSP change the primary endpoint.  He used to head up the Metabolic/Endocrine division of the FDA and knows what regulatory agencies expect.  he also knows what is appropriate scientific conduct and what is not.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Roy M. Poses MD</title>
		<link>http://www.pharmalot.com/2008/01/behind-the-curtain-that-secret-vytorin-panel/#comment-91917</link>
		<dc:creator>Roy M. Poses MD</dc:creator>
		<pubDate>Fri, 11 Jan 2008 20:38:10 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2008/01/behind-the-curtain-that-secret-vytorin-panel/#comment-91917</guid>
		<description>Also, it appears that the "independent" panel really wasn't.  Three panel members had financial ties to Merck, or both Merck and Schering-Plough, in addition to their service on the panel.  See this post on Health Care Renewal:
http://hcrenewal.blogspot.com/2008/01/who-decided-to-change-outcome-variable.html</description>
		<content:encoded><![CDATA[<p>Also, it appears that the &#8220;independent&#8221; panel really wasn&#8217;t.  Three panel members had financial ties to Merck, or both Merck and Schering-Plough, in addition to their service on the panel.  See this post on Health Care Renewal:<br />
<a href="http://hcrenewal.blogspot.com/2008/01/who-decided-to-change-outcome-variable.html" rel="nofollow">http://hcrenewal.blogspot.com/2008/01/who-decided-to-change-outcome-variable.html</a></p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Hank</title>
		<link>http://www.pharmalot.com/2008/01/behind-the-curtain-that-secret-vytorin-panel/#comment-91798</link>
		<dc:creator>Hank</dc:creator>
		<pubDate>Fri, 11 Jan 2008 18:10:54 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2008/01/behind-the-curtain-that-secret-vytorin-panel/#comment-91798</guid>
		<description>The further this gets, the worse it looks.  That may or may not be accurate.  But MSP folks seem to keep digging a deeper hole.</description>
		<content:encoded><![CDATA[<p>The further this gets, the worse it looks.  That may or may not be accurate.  But MSP folks seem to keep digging a deeper hole.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.153 seconds -->

